earuphoria.
All podcasts
Business · Investing

Charged Alpha Stock Encyclopedia

Colton Thomas
Rights holder? Report thischargedalpha.podbean.com

Episodes

November 18, 2026

Elbit Systems (ESLT): $33B Backlog. What Does the Price Demand? | Q3 2026

SELL — November 17, 2026 base present value: $373.27 per ordinary share, versus the dated $720 after-hours quote at 4:36:47 p.m. Eastern. Conditional present range: $115.87–$835.43. Free full research: https://chargedalpha.com/research/eslt-q3-2026?view=reader Elbit reported a $33 billion September order backlog and 17.2% quarterly revenue growth. Hudson and Lana test how that demand becomes shareholder cash after capacity investment, fixed-price contract costs, customer advances, delayed collections, taxes and existing claims. The base includes high-teens initial revenue growth and expanding margins. It produces approximately negative 4.7% annualized owner return through December 2031, including modeled distributions, versus an 11% required return. The bull produces approximately 11.2%. These are conditional author esti...

November 18, 2026

Tencent Music (TME): Cash-Rich, but What Is It Worth? | Q3 2026

BUY with restrained conviction — November 17, 2026 base present value: $13.74 per ADS, versus the dated $9.40 after-hours quote at 6:57:12 p.m. Eastern. Conditional present range: $7.25–$21.41. Free full research: https://chargedalpha.com/research/tme-q3-2026?view=reader Tencent Music reported 9.2% membership revenue growth, but Ximalaya consolidation prevents calling that organic. Hudson and Lana examine the music and audio economics, lower-margin merchandise and concerts, cash conversion, September borrowing, strategic investments, and the ordinary-share-to-ADS bridge. Our independent Chinese music peer check gives only $7.06–$10.99 per ADS, materially below the main cash-flow valuation. We explain the disagreement rather than averaging it away. Base modeled owner return is approximately 17.0% annual...

November 18, 2026

Disney (DIS): Better Profits. Where Does the Cash Go? | Q4 FY2026

HOLD | November 17, 2026 base present fair value: $114/share. Dated after-hours quote: $117.37 at 6:28:50 p.m. EST. Conditional bear/base/bull values: $32 / $114 / $223. These are estimates, not guaranteed price boundaries. Full free research packet: https://chargedalpha.com/research/dis-q4-fy2026?view=reader Disney reported $102.344 billion of fiscal 2026 revenue and $10.572 billion of free cash flow. Hudson and Lana separate the extra week's contribution from comparable growth, explain the new segment structure, and examine streaming, sports rights, parks, content investment, debt, minority ownership and employee claims. Management's fiscal 2027 cash content plan is approximately $26 billion, separate from approximately $9 billion of property capital spending. The $11 billion free-cash-flow guide...

November 17, 2026

NVIDIA (NVDA): Revenue Doubled. Who Carries the Risk? | Q3 FY2027

BUY | November 17, 2026 base present fair value: $237/share. Dated after-hours quote: $162.2562 at 6:03:45 p.m. EST. Conditional bear/base/bull values: $67 / $237 / $439. These are estimates, not guaranteed price boundaries. Full free research packet: https://chargedalpha.com/research/nvda-q3-fy2027?view=reader NVIDIA reported $115.844 billion of Q3 FY2027 revenue and $43.777 billion of free cash flow. Hudson and Lana examine customer-platform growth, the Rubin margin reset, receivables, supplier commitments, investment holdings, ownership and contingent support. Maximum gross guarantees of $118 billion are not current debt or expected cash losses. The base model values operating cash generation after reinvestment and support costs, then reconciles cash, investments and...

November 17, 2026

Infleqtion (INFQ): 30 Logical Qubits. What Is It Worth? | Q3 2026

SELL | Base present fair value: $1.84 per share as of November 16, 2026. Dated quote: $8.01 at 7:59:42 p.m. EST, after-hours. Conditional present range: $0.50–$4.06; low valuation conviction and high technical/commercial uncertainty. Full free research packet: https://chargedalpha.com/research/infq-q3-2026?view=reader Infleqtion reported 30 entangled logical qubits, Q3 revenue of $9.149 million and $560.022 million of cash and securities. Hudson and Lana examine the sensing and computing opportunity, corrected Q2 comparisons, contract economics and the $28.3 million held for tax authorities that is unavailable for operations. Our main model follows commercialization, research, equipment, operating capital and ownership. Independent scientific-instrument economics and recent cash use provide co...

November 17, 2026

Red Cat (RCAT): Growth Without Cash | Q3 2026

SELL | Base present fair value: $0.39 per share as of November 16, 2026. Dated quote: $2.6054 at 7:59:25 p.m. EST, after-hours. Conditional present range: $0.06–$1.70; low valuation conviction, high execution and funding risk. Full free research packet: https://chargedalpha.com/research/rcat-q3-2026?view=reader Red Cat reported Q3 revenue growth of 22%, but only $65,000 of gross profit. Hudson and Lana examine withdrawn revenue guidance, inventory, cash burn, procurement and the pending Steyr cash offer. The primary offer document says purchase funds are arranged; our model separately tests future operating liquidity and dilution. The main valuation follows commercialization, investment and ownership. An independent defense-transaction reference is ma...

November 17, 2026

POWL Earnings: Record Backlog. Is the Stock Too Expensive? | Q4 FY2026

SELL at the dated $152.50 after-hours quote; base present fair value $95.71 as of November 16, 2026. Powell delivered strong results, but the price is near our conditional bull-case present value. Q4 revenue rose 33% and September backlog reached $2.7 billion. Hudson and Lana examine the annual margin outlook versus the exceptional quarter, customer advances behind the cash balance, manufacturing investment, ownership and the operating expectations built into the price. Our main valuation follows orders and backlog through capacity, margins, reinvestment and owner cash. The independent acquisition reference and reverse expectations are separate checks, not methods averaged into a target. Bear/base/bull present values are $58.87/$95.71/$151.76...

November 16, 2026

ACM Earnings: Record Backlog, a $500M Cash Bill | Q4 FY2026

Charged Alpha rating: HOLD, with high uncertainty. Base present fair value: $84.35 per share as of November 16, 2026. Reference quote: $76.9072 ($76.91 rounded) at 5:10:04 p.m. Eastern on November 16, after hours. Conditional present scenario range: $43.71–$108.92. Read the free full research packet, model assumptions and risks: https://chargedalpha.com/research/acm-q4-fy2026?view=reader AECOM Q4 FY2026 results show record backlog and stronger design activity, but management still expects approximately $500 million of fiscal 2027 cash use on two Construction Management projects. That future spending is separate from the $337 million rounded project charge recognized in Q3. We examine net service revenue versus subcontractor pass-throughs, awarded versus contracted ba...

November 16, 2026

POET Earnings: Cash Is Ready. Are the Shipments? | Q3 2026

Charged Alpha rating: HOLD, with very high uncertainty. Base present fair value: $5.03 per common share as of November 16, 2026. Reference quote: $4.72 on November 16 at 3:15:43 p.m. Eastern (intraday). Conditional present scenario range: $1.59–$11.48. Read the free full research packet, model assumptions and risks: https://chargedalpha.com/research/poet-q3-2026?view=reader POET Q3 2026 revenue reached $1.026 million, up 244% year over year. Yet the current backlog, including the former 30,000-engine 2026 target, is now expected to ship by Q2 2027. September cash and short-term investments totaled $774.373 million before subsequent spending and claims. We examine customer qualification, manufacturing yield, capacity spending, warrants and shareholder dilution. Our company-specific mo...

November 16, 2026

Tyson (TSN): Can Beef Recovery Justify the Price? | Q4 FY2026

SELL / trim at the dated $62.75 quote. Base present fair value: $51.47 per share, valued November 16, 2026. Free full earnings analysis packet, model and sources: https://chargedalpha.com/research/tsn-q4-fy2026?view=reader Can beef recovery justify Tyson's price? Hudson and Lana examine Q4 FY2026 results, the extra week in reported revenue, chicken margin pressure, Prepared Foods, cash generation, rising capital spending, debt, existing claims and share repurchases. The main model normalizes each segment's cash flows through the protein cycle. Base present value is $51.47; bear/bull present values are $19.02–$80.77. Subjective weighted value is $50.68 and does not replace the main base model. The independent Pi...

November 16, 2026

Baidu (BIDU): AI Cloud Surges. Where Is the Cash? | Q3 2026

Charged Alpha rating: BUY, with high uncertainty. Base present fair value: $112.66 per ADS as of November 16, 2026. Reference price: $75.03 on November 16 at 12:20 p.m. Eastern. Conditional present scenario range: $65.07–$191.98. Read the free full research packet, model assumptions and risks: https://chargedalpha.com/research/bidu-q3-2026?view=reader Baidu Q3 2026 earnings: AI Cloud Infra revenue grew 94%, but capital spending still exceeded operating cash. We examine whether cloud growth can become durable cash for shareholders while advertising revenue declines. Our company-specific model separates cloud, advertising, applications and other businesses, charges reinvestment and compensation, and reconciles cash, debt and minority claims. The independent tangible-book ch...

November 15, 2026

AMAT Earnings: Record Revenue. Is the Stock Still a Buy? | Q4 FY2026

AMAT Q4 FY2026: BUY with moderate conviction at the $370.50 November 13 close. Our base present fair value is $409.59 per share. Revenue grew 53%, but the investment case still depends on durable process demand, services and cash conversion through the equipment cycle. Free full earnings analysis packet, model assumptions and sources: https://chargedalpha.com/research/amat-q4-fy2026 Hudson and Lana examine AI-driven equipment demand, services economics, margins, China exposure, working capital, investment spending, debt, share repurchases and the strongest bull and bear theses. The company-specific model includes a fiscal 2029 equipment pause, an independent Lam Research comparison and a reverse expectations test. Valuation date...

November 15, 2026

CBRS Earnings: $26 Billion Backlog. Who Keeps the Cash? | Q3 2026

Cerebras has $26.1 billion in remaining performance obligations. How much becomes cash for shareholders? At the November 13, 2026 close of $108.72, our company-specific equity cash model gives CBRS a base present fair value near $48 and an AVOID call. We model strong growth—including a $2.85 billion 2027 revenue assumption informed by management’s tripling ambition—while charging infrastructure investment, customer-loan settlements and ownership claims. Read the free full research packet: https://chargedalpha.com/research/cbrs-q3-2026 Explore the free Charged Alpha investing app: https://chargedalpha.com/app?source=youtube&ref=video Hudson and Lana examine: • $210.8m GAAP revenue versus $230.9m Core revenue, and why the distinct...

November 15, 2026

HIMS Earnings: 49% Growth. Where Did the Profit Go? | Q3 2026

HIMS Q3 2026: HOLD at the $19.73 November 13 close. Our base present fair value is about $17.10 per share. Revenue grew 49%, but gross margin fell to 57% and cash conversion weakened. We examine whether subscriber growth, branded-drug choice and international expansion can produce better owner economics. Free full earnings analysis packet, model assumptions and sources: https://chargedalpha.com/research/hims-q3-2026 Hudson and Lana work through subscriber economics, gross profit versus marketing, cash flow, acquisition obligations, debt and ownership dilution, the strongest bull and bear theses, and the growth/margin assumptions embedded in the stock price. Our company-specific model includes a dated cash and...

November 15, 2026

TTWO Earnings: GTA 6 Can Win. Can the Stock? | Q2 FY2027

AVOID at $227.82 | Base present fair value $148.88 | Valuation date: November 13, 2026 Read the free full research packet: https://chargedalpha.com/research/ttwo-q2-fy2027?view=reader GTA VI could be a blockbuster. Does Take-Two stock already price in too much? Our base case allows a successful launch. The debate is how much lasting cash reaches shareholders after development, licensing, stock compensation and reinvestment. Hudson and Lana walk through Q2 FY2027 bookings versus GAAP revenue, recurring consumer spending, debt maturities and share count. Our present scenario values are $74.64, $148.88 and $249.82. We compare the result with the announced EA transaction and ask what the stock price...

November 14, 2026

Enovix (ENVX): Who Pays for the Growth? — Q3 2026 Earnings

AVOID at $1.60 | Base present fair value ≈$0.20 | Valuation date: November 13, 2026 Free full research packet: https://chargedalpha.com/research/envx-q3-2026 Enovix's commercial growth is improving. Does the funding needed to reach scale leave enough for today's shareholders? Hudson and Lana work through the strongest bull and bear cases, earnings, margins, cash, debt, shares and the valuation. Our base grows revenue from $75m in 2027 to $810m in 2036 and assumes additional cost cuts. It also requires approximately $589m of new gross equity at an assumed $1/share. That financing is conditional, not guaranteed. Present scenario values: failure $0; base ≈$0.20; bull ≈$1.65. Subjective 30/50/20% weights produce ≈$0.45 (unrounded $0.430). Video figures...

November 12, 2026

RVMD Stock: What Survives the RASONQUE Launch Surge? | Q3 2026

Revolution Medicines (RVMD) Q3 2026 — Reference quote: November 11, 2026 close. Results released November 4, 2026. Revolution Medicines Q3 2026: RASONQUE generated $197.559M in roughly five weeks, including finite early-launch patient cohorts and channel stocking. Product economics remain attractive after restoring previously expensed manufacturing costs; recurring demand, portfolio spending, royalties and dilution decide shareholder value. U.S. RASONQUE pancreatic approval is established. European Commission approval remains pending in the reviewed release; NSCLC remains investigational despite NCCN inclusion. This analysis is compiled with frontier AI research models, and all scripts are AI-generated. Sources: https://www.sec.gov/Archives/edgar/data/1628171/000119312526447193/rvmd-ex99_1.htm | https://www.sec.gov/Archives/ed...

November 12, 2026

CRWV Stock: Customer Cash Is Not Shareholder Cash | CoreWeave Q3 2026

CoreWeave (CRWV) Q3 2026 — Next trading-day close versus release-date close: November 11 versus November 10 +24.71%; reference $60.77. Exact release time unconfirmed. Customer advances help finance rapid CoreWeave growth, but interest, reinvestment and reporting risks shape the remaining common-share claim. This analysis is compiled with frontier AI research models, and all scripts are AI-generated. THE CALL: HOLD (2/5, LOW) — base-case value ~$67.00 vs ~$60.77 at the November 11, 2026 close. KEY METRICS: - Revenue: $3,661 million - GAAP operating income: $207 million - Net interest expense: $846 million - Cash capital expenditure: $9,441 million - Net debt including finance leases: $43,338 million - Reporting basis: Q3 results are unaudited. The latest available quarterly filing, for Q2...

November 11, 2026

GEHC Stock: The Recovery Is Real — But What Reaches Owners? | Q3 2026

GE HealthCare Technologies Inc. (GEHC) Q3 2026 — The October 28 close rose 6.62% from the pre-release close; the November 10 reference price of $83.65 was 17.63% above that baseline. GE HealthCare improved margins across all three segments and raised guidance. We separate cash tariff refunds from recognized income, test the PCS recovery and examine acquisition funding before valuing the cash that reaches owners. THE CALL: HOLD (3/5, MODERATE) — Current fair value ~$80.00 vs ~$83.65 at the November 10, 2026 close. KEY METRICS: - Revenue $5.513B; organic growth 6.2% - Adjusted EBIT margin 16.6%, up 180 bps - GAAP EPS $1.36; adjusted EPS $1.34 - Q3 FCF $793M includes $55M cash tariff refunds - FY adjusted EPS guid...

November 11, 2026

SNY Stock: Who Keeps the Dupixent Cash? | Sanofi Q3 2026

Sanofi (SNY) Q3 2026 — The October 30 first post-release close rose 2.81% versus October 29; reference is the November 10 close of $48.23 per ADS. Dupixent drove Sanofi growth and upgraded guidance, but Regeneron economics and reinvestment shape the owner cash claim. We reconcile IFRS and business earnings, trace cash allocation and value the Nasdaq ADS with the correct half-share ratio and EUR/USD conversion. THE CALL: HOLD (3/5, MODERATE) — base-case value ~$52.00 vs ~$48.23 today. KEY METRICS: - Q3 net sales €14.444B; +14.3% CER, +16.2% reported - Business EPS €3.55; IFRS EPS €2.52 per ordinary share - Dupixent sales €5.687B; 39.4% of net sales, computed - Regeneron alliance expense €2.399B - 9M company FCF €6.993B; S...

Similar podcasts